 PAVmed Inc. Nasdaq: PAVM, PAVMZ the Company or PAVmed, a highly differentiated, multiproduct medical device company, today provided an update on its CarpXTM first-in-human FIH 510k clinical safety study. The study has, however, already exceeded the minimum 80 follow-up rate requested by the U.S. Food and Drug Administration FDA with no device-related adverse events. PAVmed is now proceeding with finalization of the clinical reports, including customary overreads of the diagnostic test results by a U.S. physician. 